OncoMatch

OncoMatch/Clinical Trials/NCT07647744

To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer

Is NCT07647744 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies Anti-Human CD70 T-Cell for renal cell carcinoma (rcc).

Phase 1RecruitingHrain Biotechnology Co., Ltd.NCT07647744Data as of Sep 2026Location: China

Treatment: Anti-Human CD70 T-Cell

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Anti-Human CD70 T-Cell

Cancer type

Renal Cell Carcinoma

Biomarker criteria

Required: CD70 expression (positive)

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 70

Prior therapy

Min 1 prior line

Must have received: systemic therapy

Must have received at least one prior line of systemic therapy (must include at least: (1) immuno-oncology (IO) combination therapy: concomitant targeting of PD-1 and CTLA-4, or (2) an immune checkpoint inhibitor (PD-1/PD-L1 inhibitor) combined with a VEGF/VEGFR-targeted agent)

Cannot have received: anti-CD70 targeted therapy

Prior treatment with anti-CD70 targeted therapies

Cannot have received: CAR-T cell therapy

Prior treatment with CAR-T therapy or other genetically modified cell therapies prior to screening

Lab requirements

Blood counts

hemoglobin ≥ 90 g/L, ANC ≥ 1.5×10^9/L, platelet count ≥ 100×10^9/L

Kidney function

Creatinine clearance (CrCl) ≥ 50 mL/min (Cockcroft-Gault formula)

Liver function

Total bilirubin ≤2 × ULN; ALT and AST ≤2.5 × ULN

Cardiac function

Left ventricular ejection fraction (LVEF) > 50%

hemoglobin ≥ 90 g/L, ANC ≥ 1.5×10^9/L, platelet count ≥ 100×10^9/L; CrCl ≥ 50 mL/min; LVEF > 50%; Total bilirubin ≤2 × ULN; ALT and AST ≤2.5 × ULN; Baseline peripheral oxygen saturation > 95%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07647744 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior anti-CD70 targeted therapy, CAR-T cell therapy disqualifies patients from enrollment.

Does this trial require CD70?

Yes, CD70 expression is a required biomarker for enrollment.

Is there an age limit?

Yes. Patients must be 70 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify